Gliptivil Combo

Gliptivil Combo is a prescription oral tablet that combines metformin hydrochloride and vildagliptin. Classified as a biguanide and DPP‑4 inhibitor, it is marketed in the European Union for adults with type 2 diabetes mellitus. The formulation works by lowering hepatic glucose production and enhancing incretin‑mediated insulin secretion, supporting overall blood‑glucose control effectively when used with diet, exercise, lifestyle modifications, regular monitoring, and routine clinical follow‑up.

Gliptivil Combo is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to lifestyle therapy.

- As monotherapy or in combination when metformin alone does not achieve target glycemic levels. - Adjunct to diet and exercise to improve overall blood glucose control. - Use in patients who require both hepatic glucose reduction and enhanced incretin effect. - May be considered when a single‑pill regimen simplifies treatment adherence. - Suitable for patients needing additional glucose‑lowering effect beyond metformin.

The safety profile of Gliptivil Combo reflects the known effects of its individual components, metformin and vildagliptin.

Common: - Nausea or upset stomach. - Diarrhea or abdominal discomfort. - Headache. - Upper respiratory tract infection symptoms (e.g., nasopharyngitis). - Mild hypoglycemia when combined with other glucose‑lowering agents.

Serious: - Lactic acidosis (rare, associated with metformin). - Acute pancreatitis (possible with vildagliptin). - Severe hypoglycemia, especially when used with sulfonylureas or insulin. - Significant renal impairment leading to drug accumulation.

Before initiating Gliptivil Combo, clinicians should evaluate several clinical factors to minimize risk.

- Assess renal function; avoid or adjust in moderate to severe renal impairment. - Review hepatic status, as liver disease may affect drug metabolism. - Monitor for signs of heart failure, particularly in patients with existing cardiac conditions. - Consider pregnancy and lactation status; safety data are limited. - Use cautiously in elderly patients who may have reduced renal clearance. - Advise patients to limit excessive alcohol intake, which can increase lactic acidosis risk. - Regularly monitor blood glucose and HbA1c to gauge therapeutic response.

Gliptivil Combo may interact with other medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Co‑administration with other metformin‑containing products, which can increase the risk of lactic acidosis. - Use of strong CYP2C9 inhibitors (e.g., fluconazole) that raise vildagliptin plasma levels. - Iodinated contrast agents in patients with compromised renal function.

Use with caution: - Sulfonylureas or insulin, due to an increased risk of hypoglycemia. - Diuretics that may affect renal clearance of metformin. - Corticosteroids or other agents that raise blood glucose, potentially requiring dose adjustments. - Medications that alter gastric pH, which could affect metformin absorption.